Democrats are lying: Republicans in hotly contested races support IVF availability: ‘Promotes more babies and strong families’
Democrats are seeking to make in-vitro fertilization an election issue, with Vice President Kamala Harris declaring during ...
GlobalData on MSN5d
US issuers play a pivotal role in addressing growing CNP fraud
Issuers still hold the key role in fighting fraud without compromising customer experience. A proactive issuer strategy ...
Despite Being First Mover, BioMarin's Voxzogo For Dwarfism To Face Pressure From Ascendis' Candidate In Near Term
BioMarin stock dips in response to TransCon CNP data, as analysts note TransCon CNP could challenge BioMarin's Voxzogo by ...
Pivotal ApproaCH Trial of TransCon™ CNP (Navepegritide) Achieved Primary Objective, Demonstrated AGV Superior to Placebo
TransCon CNP demonstrated AGV superior to placebo with LS mean treatment difference of 1.49 cm/year at Week 52 (p<0.0001)– For ...
news.stocktradersdaily6d
Where are the Opportunities in (CNP)
Check the time stamp on this data. Updated AI-Generated Signals for Centerpoint Energy Inc (holding Co) (CNP) available here: ...
FierceBiotech5d
Ascendis' dwarfism drug accelerates growth in phase 3, teeing up challenge to BioMarin
Copenhagen-based Ascendis designed the trial to compare its once-weekly prodrug of C-type natriuretic peptide (CNP) to ...
CenterPoint Energy's (NYSE:CNP) investors will be pleased with their 21% return over the last three years
Over the last three years, CenterPoint Energy failed to grow earnings per share, which fell 20% (annualized). The strong ...
Education Next12d
A Vast Right-Wing Conspiracy?
The machinations of a powerful syndicate behind the success of school choice makes for a juicy story. Too bad it isn’t true.
Ascendis Pharma's Rare Dwarfism Candidate Shows Promise In Trial, FDA Submission Expected Next Year
Ascendis Pharma reports positive topline data from the Phase 3 ApproaCH trial of TransCon CNP in children with achondroplasia ...
Ascendis Pivotal ApproaCH Study Of TransCon CNP In Achondroplasia Meets Primary Goal; Stock Up
(RTTNews) - Ascendis Pharma A/S (ASND) Monday said the pivotal ApproaCH study of TransCon CNP, in children with achondroplasia met its primary goal. The company's shares were more than 17 percent up ...
Ascendis Challenges BioMarin, But Market Response Seems Excessive
Ascendis' TransCon CNP showed similar efficacy to BioMarin's Voxzogo but offers once-weekly dosing. Learn more on BMRN and ...
BioMarin off 17% as Ascendis data seen as threat to Voxzogo
BioMarin Pharmaceutical (NASDAQ:BMRN) is down ~17% Monday following positive data from an Ascendis Pharma ...